SE9302396D0 - A novel compound form - Google Patents

A novel compound form

Info

Publication number
SE9302396D0
SE9302396D0 SE19939302396A SE9302396A SE9302396D0 SE 9302396 D0 SE9302396 D0 SE 9302396D0 SE 19939302396 A SE19939302396 A SE 19939302396A SE 9302396 A SE9302396 A SE 9302396A SE 9302396 D0 SE9302396 D0 SE 9302396D0
Authority
SE
Sweden
Prior art keywords
novel compound
compound form
crystallinity
manufacture
useful
Prior art date
Application number
SE19939302396A
Other languages
English (en)
Swedish (sv)
Inventor
Aake *Kaellstroem Lars
Annelie *Nygren Monica
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9302396(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SE19939302396A priority Critical patent/SE9302396D0/xx
Application filed by Ab Astra filed Critical Ab Astra
Publication of SE9302396D0 publication Critical patent/SE9302396D0/xx
Priority to TW083105710A priority patent/TW504509B/zh
Priority to HR940385A priority patent/HRP940385B1/xx
Priority to IL11019094A priority patent/IL110190A/xx
Priority to SA94150058A priority patent/SA94150058B1/ar
Priority to IS4186A priority patent/IS2075B/is
Priority to ZA944933A priority patent/ZA944933B/xx
Priority to EG40794A priority patent/EG21437A/xx
Priority to MYPI94001774A priority patent/MY113274A/en
Priority to MA23567A priority patent/MA23257A1/fr
Priority to DE0707580T priority patent/DE707580T1/de
Priority to HU9503873A priority patent/HU226861B1/hu
Priority to SI9430414T priority patent/SI0707580T1/xx
Priority to PL94312440A priority patent/PL175999B1/pl
Priority to TNTNSN94079A priority patent/TNSN94079A1/fr
Priority to AT94921154T priority patent/ATE212628T1/de
Priority to JP50400595A priority patent/JP3635432B2/ja
Priority to BR9406940A priority patent/BR9406940A/pt
Priority to AU71981/94A priority patent/AU679766B2/en
Priority to EP94921154A priority patent/EP0707580B1/en
Priority to SK22-96A priority patent/SK281230B6/sk
Priority to RU96102079A priority patent/RU2139868C1/ru
Priority to PCT/SE1994/000680 priority patent/WO1995001977A1/en
Priority to PT94921154T priority patent/PT707580E/pt
Priority to KR1019960700051A priority patent/KR100353783B1/ko
Priority to NZ268693A priority patent/NZ268693A/en
Priority to SG1996004887A priority patent/SG52464A1/en
Priority to CN94192733A priority patent/CN1064680C/zh
Priority to CZ199669A priority patent/CZ288933B6/cs
Priority to ES94921154T priority patent/ES2100136T3/es
Priority to CA002166794A priority patent/CA2166794C/en
Priority to DE69429774T priority patent/DE69429774T2/de
Priority to DK94921154T priority patent/DK0707580T3/da
Priority to US08/313,342 priority patent/US5900424A/en
Priority to UA96010059A priority patent/UA43343C2/uk
Priority to MX9405217A priority patent/MX9405217A/es
Priority to YU43694A priority patent/YU49193B/sh
Priority to EP01117362A priority patent/EP1164132A3/en
Priority to EE9400405A priority patent/EE03127B1/xx
Priority to DZ940071A priority patent/DZ1792A1/fr
Priority to NO960068A priority patent/NO308702B1/no
Priority to FI960101A priority patent/FI114154B/fi
Priority to GR970300015T priority patent/GR970300015T1/el
Priority to HK98109227A priority patent/HK1008329A1/xx
Priority to JP2001293480A priority patent/JP3878826B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Conductive Materials (AREA)
  • Electroplating Methods And Accessories (AREA)
  • Contacts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Powder Metallurgy (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)
  • Medicinal Preparation (AREA)
SE19939302396A 1993-07-09 1993-07-09 A novel compound form SE9302396D0 (sv)

Priority Applications (45)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form
TW083105710A TW504509B (en) 1993-07-09 1994-06-23 A novel form of magnesium omeprazole, its preparation process and pharmaceutical composition comprising the same
HR940385A HRP940385B1 (en) 1993-07-09 1994-07-01 Novel compound form
IL11019094A IL110190A (en) 1993-07-09 1994-07-01 Magnesium omeprazole with crystallinity higher than 70% process for its preparation and its use in the manufacture of medicaments for inhibiting gastric acid secretion and for obtaining gastric mucosa protective activity
SA94150058A SA94150058B1 (ar) 1993-07-09 1994-07-04 مركب ملح مغنسيوم الاومبرازول
IS4186A IS2075B (is) 1993-07-09 1994-07-05 Aðferð til að framleiða magnesíumómeprasól
MA23567A MA23257A1 (fr) 1993-07-09 1994-07-07 Nouvelle forme de compose demagnesium d'omeprazole etson utilisation .
MYPI94001774A MY113274A (en) 1993-07-09 1994-07-07 Omeprazole magnesium salt form
ZA944933A ZA944933B (en) 1993-07-09 1994-07-07 A novel compound form
EG40794A EG21437A (en) 1993-07-09 1994-07-07 Method for preparing magnesium omeprazole compounds useful for inhibiting gastric acid sectretion
YU43694A YU49193B (sh) 1993-07-09 1994-07-08 Magnezijum omeprazol i postupak za dobijanje ovog jedinjenja
EP01117362A EP1164132A3 (en) 1993-07-09 1994-07-08 Crystalline magnesium omeprazole
RU96102079A RU2139868C1 (ru) 1993-07-09 1994-07-08 Магниевая соль омепразола, способ ее получения, фармацевтическая композиция, способ лечения
CN94192733A CN1064680C (zh) 1993-07-09 1994-07-08 奥美拉唑镁的制备方法
SI9430414T SI0707580T1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
PL94312440A PL175999B1 (pl) 1993-07-09 1994-07-08 Omeprazol magnezowy i sposób wytwarzania omeprazolu magnezowego oraz kompozycja farmaceutyczna go zawierająca
TNTNSN94079A TNSN94079A1 (fr) 1993-07-09 1994-07-08 Une nouvelle forme de compose
AT94921154T ATE212628T1 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
JP50400595A JP3635432B2 (ja) 1993-07-09 1994-07-08 オメプラゾールマグネシウムの製法
BR9406940A BR9406940A (pt) 1993-07-09 1994-07-08 Magnésio-omeprazol processo para a preparação de magnésio-omeprazol composição farmacêutica formulação farmacêutica para a administração oral forumulação de tablete uso do magnesio-omeprazol processo para a inibição da secreção de ácido gástrico em mamiferos e no homem e processo para o tratamento das doenças relacionadas com o ácido gastrico em mamiferos e no homem
AU71981/94A AU679766B2 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
EP94921154A EP0707580B1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
SK22-96A SK281230B6 (sk) 1993-07-09 1994-07-08 Magnézium omeprazol, spôsob jeho výroby, farmaceutické prípravky s jeho obsahom a jeho použitie
DE0707580T DE707580T1 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
PCT/SE1994/000680 WO1995001977A1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
PT94921154T PT707580E (pt) 1993-07-09 1994-07-08 Omeprazole magnesio
KR1019960700051A KR100353783B1 (ko) 1993-07-09 1994-07-08 마그네슘오메프라졸
NZ268693A NZ268693A (en) 1993-07-09 1994-07-08 Magnesium omeprazole having a degree of crystallinity greater than 70%
SG1996004887A SG52464A1 (en) 1993-07-09 1994-07-08 A novel compound form
HU9503873A HU226861B1 (en) 1993-07-09 1994-07-08 Magnesium salt of omeprazole
CZ199669A CZ288933B6 (cs) 1993-07-09 1994-07-08 Magnezium omeprazol
ES94921154T ES2100136T3 (es) 1993-07-09 1994-07-08 Omeprazol de magnesio.
CA002166794A CA2166794C (en) 1993-07-09 1994-07-08 Magnesium omeprazole
DE69429774T DE69429774T2 (de) 1993-07-09 1994-07-08 Magnesium-omeprazol
DK94921154T DK0707580T3 (da) 1993-07-09 1994-07-08 Magnesiumomeprazol
US08/313,342 US5900424A (en) 1993-07-09 1994-07-08 Omeprazole magnesium salt form
UA96010059A UA43343C2 (uk) 1993-07-09 1994-07-08 Магнієва сіль омепразолу, спосіб її одержання, фармацевтична композиція, спосіб лікування
MX9405217A MX9405217A (es) 1993-07-09 1994-07-08 Proceso para la fabricacion de sal de magnesio de omeprazol, productoobtenido a partir del mismo y composicion farmaceutica que contiene dichoproducto.
EE9400405A EE03127B1 (et) 1993-07-09 1994-11-17 Kristalne magneesiumomeprasool, selle valmistamise protsess, seda sisaldavad ravimpreparaadid ja nende kasutamine
DZ940071A DZ1792A1 (fr) 1993-07-09 1994-11-27 Une nouvelle forme de composé.
NO960068A NO308702B1 (no) 1993-07-09 1996-01-05 Magnesiumomeprazol, fremgangsmÕte for fremstilling derav, farmasøytisk preparat inneholdende magnesiumomeprazol og anvendelse derav
FI960101A FI114154B (fi) 1993-07-09 1996-01-09 Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi
GR970300015T GR970300015T1 (en) 1993-07-09 1997-05-30 Magnesium omeprazole
HK98109227A HK1008329A1 (en) 1993-07-09 1998-07-17 Magnesium omeprazole
JP2001293480A JP3878826B2 (ja) 1993-07-09 2001-09-26 オメプラゾールマグネシウム

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Publications (1)

Publication Number Publication Date
SE9302396D0 true SE9302396D0 (sv) 1993-07-09

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form

Country Status (42)

Country Link
US (1) US5900424A (xx)
EP (2) EP1164132A3 (xx)
JP (2) JP3635432B2 (xx)
KR (1) KR100353783B1 (xx)
CN (1) CN1064680C (xx)
AT (1) ATE212628T1 (xx)
AU (1) AU679766B2 (xx)
BR (1) BR9406940A (xx)
CA (1) CA2166794C (xx)
CZ (1) CZ288933B6 (xx)
DE (2) DE69429774T2 (xx)
DK (1) DK0707580T3 (xx)
DZ (1) DZ1792A1 (xx)
EE (1) EE03127B1 (xx)
EG (1) EG21437A (xx)
ES (1) ES2100136T3 (xx)
FI (1) FI114154B (xx)
GR (1) GR970300015T1 (xx)
HK (1) HK1008329A1 (xx)
HR (1) HRP940385B1 (xx)
HU (1) HU226861B1 (xx)
IL (1) IL110190A (xx)
IS (1) IS2075B (xx)
MA (1) MA23257A1 (xx)
MX (1) MX9405217A (xx)
MY (1) MY113274A (xx)
NO (1) NO308702B1 (xx)
NZ (1) NZ268693A (xx)
PL (1) PL175999B1 (xx)
PT (1) PT707580E (xx)
RU (1) RU2139868C1 (xx)
SA (1) SA94150058B1 (xx)
SE (1) SE9302396D0 (xx)
SG (1) SG52464A1 (xx)
SI (1) SI0707580T1 (xx)
SK (1) SK281230B6 (xx)
TN (1) TNSN94079A1 (xx)
TW (1) TW504509B (xx)
UA (1) UA43343C2 (xx)
WO (1) WO1995001977A1 (xx)
YU (1) YU49193B (xx)
ZA (1) ZA944933B (xx)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
MX9600857A (es) 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
HUT78132A (hu) * 1994-07-08 2000-06-28 Astra Aktiebolag Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142629A0 (en) * 1998-11-18 2002-03-10 Astra Ab Improved chemical process and pharmaceutical formulation
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
CA2409258A1 (en) * 2000-05-15 2001-11-22 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
US7271182B2 (en) 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
WO2004099181A1 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005072079A2 (en) 2003-09-26 2005-08-11 Alza Coporation Drug coating providing high drug loading and methods for providing the same
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US8658216B2 (en) 2004-12-23 2014-02-25 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
AU2006299424A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008067037A2 (en) 2006-10-05 2008-06-05 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2086543A2 (en) 2006-10-27 2009-08-12 The Curators of the University of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
JP5302389B2 (ja) 2008-04-29 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｊｎｋのピリミジニルピリドンインヒビター
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
CA2766524A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
EP1164132A2 (en) 2001-12-19
NO960068D0 (no) 1996-01-05
BR9406940A (pt) 1996-09-10
UA43343C2 (uk) 2001-12-17
AU7198194A (en) 1995-02-06
IS2075B (is) 2005-12-15
HK1008329A1 (en) 1999-05-07
FI960101A0 (fi) 1996-01-09
ATE212628T1 (de) 2002-02-15
MY113274A (en) 2002-01-31
PL312440A1 (en) 1996-04-29
GR970300015T1 (en) 1997-05-31
DE69429774D1 (de) 2002-03-14
IL110190A0 (en) 1994-10-21
EP0707580A1 (en) 1996-04-24
CA2166794C (en) 1997-03-04
CN1064680C (zh) 2001-04-18
DK0707580T3 (da) 2002-04-15
SA94150058B1 (ar) 2006-06-20
HRP940385A2 (en) 1997-02-28
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
FI960101A (fi) 1996-01-09
FI114154B (fi) 2004-08-31
JP3635432B2 (ja) 2005-04-06
KR100353783B1 (ko) 2004-04-03
JPH08512315A (ja) 1996-12-24
EG21437A (en) 2001-10-31
MA23257A1 (fr) 1995-04-01
DZ1792A1 (fr) 2002-02-17
JP3878826B2 (ja) 2007-02-07
SG52464A1 (en) 1998-09-28
EE03127B1 (et) 1998-10-15
NO308702B1 (no) 2000-10-16
ES2100136T1 (es) 1997-06-16
HU226861B1 (en) 2009-12-28
EP1164132A3 (en) 2002-01-02
TW504509B (en) 2002-10-01
NZ268693A (en) 1997-05-26
DE69429774T2 (de) 2002-11-14
YU43694A (sh) 1997-07-31
MX9405217A (es) 1995-01-31
RU2139868C1 (ru) 1999-10-20
ES2100136T3 (es) 2002-09-01
PT707580E (pt) 2002-06-28
ZA944933B (en) 1995-02-20
CZ6996A3 (en) 1996-05-15
AU679766B2 (en) 1997-07-10
SI0707580T1 (en) 2002-06-30
IS4186A (is) 1995-01-10
WO1995001977A1 (en) 1995-01-19
EP0707580B1 (en) 2002-01-30
DE707580T1 (de) 1997-09-04
HRP940385B1 (en) 2003-06-30
HUT75314A (en) 1997-05-28
PL175999B1 (pl) 1999-03-31
US5900424A (en) 1999-05-04
NO960068L (no) 1996-01-05
HU9503873D0 (en) 1996-02-28
CZ288933B6 (cs) 2001-09-12
TNSN94079A1 (fr) 1995-04-25
IL110190A (en) 2000-07-26
YU49193B (sh) 2004-09-03
JP2002105072A (ja) 2002-04-10
CN1126993A (zh) 1996-07-17

Similar Documents

Publication Publication Date Title
DK0707580T3 (da) Magnesiumomeprazol
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
RO114325B1 (ro) Derivaţi de sulfonilaminopirimidină şi procedeu de obţinere a acestora
NO179834C (no) Substituerte cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
AU661591B2 (en) 5,10-methylenetetrahydrofolic acid-cyclodextrin inclusion compounds
AU5778894A (en) Process for producing alkoxyiminoacetamide compounds and the production of intermediate compounds used in the process
HUT55033A (en) Process for producing aminooligohydroxy derivatives and pharmaceutical compositions comprising same
HUT46321A (en) Process for producing pyrethrinoid derivatives